JP2020533965A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533965A5 JP2020533965A5 JP2020508320A JP2020508320A JP2020533965A5 JP 2020533965 A5 JP2020533965 A5 JP 2020533965A5 JP 2020508320 A JP2020508320 A JP 2020508320A JP 2020508320 A JP2020508320 A JP 2020508320A JP 2020533965 A5 JP2020533965 A5 JP 2020533965A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 238000000034 method Methods 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000009824 affinity maturation Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546336P | 2017-08-16 | 2017-08-16 | |
| US62/546,336 | 2017-08-16 | ||
| US201762582609P | 2017-11-07 | 2017-11-07 | |
| US62/582,609 | 2017-11-07 | ||
| PCT/EP2018/072272 WO2019034753A1 (en) | 2017-08-16 | 2018-08-16 | ANTIBODY CD38 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533965A JP2020533965A (ja) | 2020-11-26 |
| JP2020533965A5 true JP2020533965A5 (enExample) | 2021-09-24 |
| JP7299873B2 JP7299873B2 (ja) | 2023-06-28 |
Family
ID=63259520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508320A Active JP7299873B2 (ja) | 2017-08-16 | 2018-08-16 | Ｃｄ３８抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11236173B2 (enExample) |
| EP (1) | EP3668543A1 (enExample) |
| JP (1) | JP7299873B2 (enExample) |
| KR (1) | KR102770110B1 (enExample) |
| CN (1) | CN111032086B (enExample) |
| AU (1) | AU2018316522B2 (enExample) |
| CA (1) | CA3072296A1 (enExample) |
| SG (1) | SG11202000484TA (enExample) |
| WO (1) | WO2019034753A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20210164A1 (ar) | 2019-01-11 | 2023-01-30 | Omeros Corp | طرق وتركيبات علاج السرطان |
| CN113795267A (zh) | 2019-03-12 | 2021-12-14 | 艾库斯生物科学有限公司 | 致癌基因驱动的癌症的治疗 |
| CN113874397A (zh) | 2019-03-29 | 2021-12-31 | 艾库斯生物科学有限公司 | 利用鉴定的腺苷指纹治疗癌症 |
| WO2021003074A1 (en) * | 2019-07-03 | 2021-01-07 | Crystal Bioscience Inc. | Anti-cd38 antibody and methods of use thereof |
| US12181485B2 (en) | 2020-09-10 | 2024-12-31 | CASI Pharmaceuticals, Inc | Methods of blood screening |
| CN112300281B (zh) * | 2020-10-29 | 2021-06-11 | 杭州爱唯生命科技有限公司 | 含有nk细胞的药物组合物及其治疗癌症的用途 |
| CN114437215B (zh) * | 2020-11-05 | 2023-02-07 | 上海麦济生物技术有限公司 | 抗人cd38抗体及其制备方法和用途 |
| WO2025213286A1 (zh) * | 2024-04-07 | 2025-10-16 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 一种阻断单核巨噬细胞功能的cd38抑制剂在治疗itp中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| AU2011202520C1 (en) | 2002-10-17 | 2016-02-18 | Genmab A/S | Human monoclonal antibodies against CD20 |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| NZ548990A (en) | 2004-02-06 | 2009-06-26 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| EP3312196B1 (en) | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| US20090123950A1 (en) | 2005-05-24 | 2009-05-14 | Morphosys Ag | Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38 |
| KR20150139636A (ko) * | 2005-10-12 | 2015-12-11 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| AU2016228249A1 (en) | 2006-09-26 | 2016-10-06 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| AU2013209322A1 (en) | 2006-10-19 | 2013-08-15 | Sanofi-Aventis | Novel anti-cd38 antibodies for the treatment of cancer |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| BRPI0717902A2 (pt) | 2006-12-01 | 2013-10-29 | Medarex Inc | "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo" |
| CN101605906A (zh) | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
| JP2010513306A (ja) | 2006-12-14 | 2010-04-30 | メダレックス インコーポレーティッド | Ｃｄ７０に結合するヒト抗体およびその使用 |
| CA2673870A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| JP5933894B2 (ja) | 2007-09-14 | 2016-06-15 | アディマブ， エルエルシー | 合理的に設計された、合成抗体ライブラリおよびその使用 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US20100233176A1 (en) | 2008-10-06 | 2010-09-16 | Cashman Neil R | Methods and systems for predicting misfolded protein epitopes |
| US8642292B2 (en) | 2009-09-22 | 2014-02-04 | Probiogen Ag | Process for producing molecules containing specialized glycan structures |
| KR102810907B1 (ko) | 2010-07-16 | 2025-05-21 | 아디맵 엘엘씨 | 항체 라이브러리 |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| US20140328849A1 (en) | 2013-03-15 | 2014-11-06 | Genentech, Inc. | Anti-crth2 antibodies and methods of use |
| KR102497443B1 (ko) | 2014-03-28 | 2023-02-08 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| CN107427566B (zh) | 2014-12-01 | 2021-08-17 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
| US10059774B2 (en) * | 2015-04-08 | 2018-08-28 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD38 |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| PE20181090A1 (es) | 2015-06-24 | 2018-07-09 | Janssen Biotech Inc | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 |
| US10358497B2 (en) | 2015-09-29 | 2019-07-23 | Amgen Inc. | Methods of treating cardiovascular disease with an ASGR inhibitor |
| MA43017A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf |
| CN114829401A (zh) | 2019-09-27 | 2022-07-29 | 南京金斯瑞生物科技有限公司 | 抗vhh域抗体及其用途 |
-
2018
- 2018-08-16 KR KR1020207003078A patent/KR102770110B1/ko active Active
- 2018-08-16 CA CA3072296A patent/CA3072296A1/en active Pending
- 2018-08-16 WO PCT/EP2018/072272 patent/WO2019034753A1/en not_active Ceased
- 2018-08-16 SG SG11202000484TA patent/SG11202000484TA/en unknown
- 2018-08-16 AU AU2018316522A patent/AU2018316522B2/en active Active
- 2018-08-16 EP EP18756417.4A patent/EP3668543A1/en active Pending
- 2018-08-16 CN CN201880051751.2A patent/CN111032086B/zh active Active
- 2018-08-16 US US16/638,205 patent/US11236173B2/en active Active
- 2018-08-16 JP JP2020508320A patent/JP7299873B2/ja active Active
-
2022
- 2022-01-18 US US17/578,014 patent/US12162949B2/en active Active